Abstract：
Underactive bladder (UAB), characterized by a complex set of symptoms with few treatment options, can significantly reduce the quality of life of affected people. UAB is characterized by hyperplasia and fibrosis of the bladder wall as well as decreased bladder compliance. Pirfenidone is a powerful anti-fibrotic agent that inhibits the progression of fibrosis in people with idiopathic pulmonary fibrosis. In the current study, we evaluated the efficacy of pirfenidone in the treatment of bladder fibrosis in a UAB rat model. UAB was induced by crushing damage to nerve bundles in the major pelvic ganglion. Forty-two days after surgery, 1 mL distilled water containing pirfenidone (100, 300, or 500 mg/kg) was orally administered once every 2 days for a total of 10 times for 20 days to the rats in the pirfenidone-treated groups. Crushing damage to the nerve bundles caused voiding dysfunction, resulting in increased bladder weight and the level of fibrous related factors in the bladder, leading to UAB symptoms. Pirfenidone treatment improved urinary function, increased bladder weight and suppressed the expression of fibrosis factors. The results of this experiment suggest that pirfenidone can be used to ameliorate difficult-to-treat urological conditions such as bladder fibrosis. Therefore, pirfenidone treatment can be considered an option to improve voiding function in patient with incurable UAB.
摘要：
膀胱活动不足(UAB),以一组复杂的症状为特征，治疗方案很少，会显著降低患者的生活质量。UAB的特征在于膀胱壁的增生和纤维化以及降低的膀胱顺应性。吡非尼酮是一种强大的抗纤维化药物，可以抑制特发性肺纤维化患者的纤维化进展。在目前的研究中,我们在UAB大鼠模型中评价了吡非尼酮治疗膀胱纤维化的疗效.UAB是通过压碎主要骨盆神经节中的神经束而引起的。手术42天后,对吡非尼酮处理组的大鼠每2天口服一次含有吡非尼酮(100、300或500mg/kg)的ImL蒸馏水,共10次,共20天。神经束的挤压损伤导致排尿功能障碍，导致膀胱重量增加和膀胱中纤维相关因素的水平，导致UAB症状。吡非尼酮治疗改善排尿功能，增加膀胱重量和抑制纤维化因子的表达。该实验的结果表明，吡非尼酮可用于改善难以治疗的泌尿系统疾病，例如膀胱纤维化。因此,吡非尼酮治疗可被认为是改善UAB患者排尿功能的一种选择。
